Endothelial progenitor cells and cardiovascular disease

Journal of Stem Cells

Volumn 9, Issue 2, 2014, Pages 93-106

  King, Thomas F J ^a   McDermott, John H ^a  

^a Royal College of Surgeons in Ireland   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENALAPRIL; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; THYROXINE; ZOFENOPRIL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL COUNT; CELL FUNCTION; CLINICAL TRIAL (TOPIC); CYTOLOGY; DIABETES MELLITUS; ENDOTHELIAL PROGENITOR CELL; HUMAN; HYPERTENSION; ISCHEMIA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBCLINICAL HYPOTHYROIDISM; SUBSTITUTION THERAPY; ANIMAL; CARDIOVASCULAR DISEASES; PHYSIOLOGY; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIAL PROGENITOR CELLS; HUMANS; RISK FACTORS;

EID: 84922479809     PISSN: 15568539     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annual review of medicine. 1996;47:315-31.
2. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-4.
3. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653-60.
4. Scott SM, Barth MG, Gaddy LR, Ahl ET, Jr.. The role of circulating cells in the healing of vascular prostheses. J Vasc Surg. 1994;19(4):585-93.
5. Wu MH, Shi Q, Wechezak AR, Clowes AW, Gordon IL, Sauvage LR. Definitive proof of endothelialization of a Dacron arterial prosthesis in a human being. J Vasc Surg. 1995;21(5):862-7.
6. Rafii S, Oz MC, Seldomridge JA, Ferris B, Asch AS, Nachman RL, et al. Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices. The Annals of Thoracic Surgery. 1995;60(6):1627-32.
7. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis. Science. 1997;275(5302):964-6.
8. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593-600.
9. Khan SS, Solomon MA, McCoy JP, Jr.. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry. 2005;64(1):1-8.
10. Fadini G, Sartore S, Schiavon M, Albiero M, Baesso I, Cabrelle A, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia–reperfusion injury in rats. Diabetologia. 2006;49(12):3075-84.
11. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, et al. Circulating Endothelial Progenitor Cells Are Reduced in Peripheral Vascular Complications of Type 2 Diabetes Mellitus. Journal of the American College of Cardiology. 2005;45(9):1449-57.
12. Fadini GP, Sartore S, Baesso I, Lenzi M, Agostini C, Tiengo A, et al. Endothelial Progenitor Cells and the Diabetic Paradox. Diabetes Care. 2006;29(3):714-6.
13. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, et al. Reduced Number of Circulating Endothelial Progenitor Cells Predicts Future Cardiovascular Events: Proof of Concept for the Clinical Importance of Endogenous Vascular Repair. Circulation. 2005;111(22):2981-7.
14. Eizawa T, Murakami Y, Matsui K, Takahashi M, Muroi K, Amemiya M, et al. Circulating endothelial progenitor cells are reduced in hemodialysis patients. Curr Med Res Opin. 2003;19(7):627-33.
15. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk Factors for Coronary Artery Disease. Circ Res. 2001;89(1):1e-7.
16. Van Craenenbroeck EM, Conraads VM, Van Bockstaele DR, Haine SE, Vermeulen K, Van Tendeloo VF, et al. Quantification of circulating endothelial progenitor cells: A methodological comparison of six flow cytometric approaches. Journal of immunological methods. 2008;332(1-2):31-40.
17. Jialal I, Devaraj S, Singh U, Huet BA. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: implications for increased cardiovascular risk. Atherosclerosis. 2010;211(1):297-302.
18. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004;53(1):195-9.
19. Vaughan EE, Liew A, Mashayekhi K, Dockery P, McDermott J, Kealy B, et al. Pretreatment of endothelial progenitor cells with osteopontin enhances cell therapy for peripheral vascular disease. Cell Transplant. 2012;21(6):1095-107.
20. Tepper O, Galiano R, Capla J, Kalka C, Gagne P, Jacobowitz G, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106(22):2781-6.
21. King TF, Bergin DA, Kent EM, Manning F, Reeves EP, Dicker P, et al. Endothelial progenitor cells in mothers of low-birthweight infants: a link between defective placental vascularization and increased cardiovascular risk? J Clin Endocrinol Metab. 2013;98(1):E33-9.
22. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89(1):E1-7.
23. Yue WS, Wang M, Yan GH, Yiu KH, Yin L, Lee SW, et al. Smoking is associated with depletion of circulating endothelial progenitor cells and elevated pulmonary artery systolic pressure in patients with coronary artery disease. Am J Cardiol. 2010;106(9):1248-54.
24. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111(22):2981-7.
25. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353(10):999-1007.
26. Chen M, Sheu J, Wang P, Chen C, Kuo M, Hsieh C, et al. Complications impaired endothelial progenitor cell function in Type 2 diabetic patients with or without critical leg ischaemia: implication for impaired neovascularization in diabetes. Diabet Med. 2009;26(2): 134-41.
27. Huang C, Zhang L, Wang Z, Pan H, Zhu J. Endothelial progenitor cells are associated with plasma homocysteine in coronary artery disease. Acta Cardiol. 2011;66(6):773-7.
28. Schlager O, Giurgea A, Schuhfried O, Seidinger D, Hammer A, Groger M, et al. Exercise training increases endothelial progenitor cells and decreases asymmetric dimethylarginine in peripheral arterial disease: A randomized controlled trial. Atherosclerosis. 2011.
29. Heida NM, Muller JP, Cheng IF, Leifheit-Nestler M, Faustin V, Riggert J, et al. Effects of obesity and weight loss on the functional properties of early outgrowth endothelial progenitor cells. J Am Coll Cardiol. 2010;55(4):357-67.
30. Wu VC, Lo SC, Chen YL, Huang PH, Tsai CT, Liang CJ, et al. Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. J Clin Endocrinol Metab. 2011;96(10):3175-83.
31. Quist-Paulsen P. Statins and inflammation: an update. Curr Opin Cardiol. 2010;25(4):399-405.
32. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108(3):391-7.
33. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, et al. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest. 2001;108(3):399-405.
34. Tousoulis D, Andreou I, Tsiatas M, Miliou A, Tentolouris C, Siasos G, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214(1):151-7.
35. Zhou J, Cheng M, Liao YH, Hu Y, Wu M, Wang Q, et al. Rosuvastatin Enhances Angiogenesis via eNOSDependent Mobilization of Endothelial Progenitor Cells. PLoS One. 2013;8(5):e63126.
36. Liao YF, Chen LL, Zeng TS, Li YM, Fan Y, Hu LJ, et al. Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. Vasc Med. 2010;15(4):279-85.
37. Chen LL, Yu F, Zeng TS, Liao YF, Li YM, Ding HC. Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes. Eur J Pharmacol. 2011;659(2-3):296-301.
38. Cacciatore F, Bruzzese G, Vitale DF, Liguori A, de Nigris F, Fiorito C, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients. Eur J Clin Pharmacol. 2011.
39. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab. 2007;92(5):1715-23.
40. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132(4):270-8.
41. Shakoor SK, Aldibbiat A, Ingoe LE, Campbell SC, Sibal L, Shaw J, et al. Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapy. J Clin Endocrinol Metab. 2010;95(1):319-22.
42. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000;97(7):3422-7.
43. Murayama T, Tepper OM, Silver M, Ma H, Losordo DW, Isner JM, et al. Determination of bone marrowderived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol. 2002;30(8):967-72.
44. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001;103(5): 634-7.
45. Aicher A, Brenner W, Zuhayra M, Badorff C, Massoudi S, Assmus B, et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation. 2003;107(16):2134-9.
46. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106(24):3009-17.
47. Leistner DM, Fischer-Rasokat U, Honold J, Seeger FH, Schächinger V, Lehmann R, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol. 2011;100(10):925-34.
48. Kudo FA, Nishibe T, Nishibe M, Yasuda K. Autologous transplantation of peripheral blood endothelial progenitor cells (CD34+) for therapeutic angiogenesis in patients with critical limb ischemia. Int Angiol. 2003;22(4):344-8.
49. Erbs S, Linke A, Adams V, Lenk K, Thiele H, Diederich KW, et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebocontrolled study. Circ Res. 2005;97(8):756-62.
50. Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Watt S, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2012;2:CD006536.